Imbruvica (ibrutinib) - Risk Of Serious And Fatal Cardiac Arrhythmias Or Cardiac Failure
IMBRUVICA (ibrutinib), a cancer medication available in tablet and capsule forms, is being recalled across Canada due to newly identified safety information showing a risk of serious and potentially fatal heart rhythm problems or heart failure. The recall affects all strengths of the drug: 140 mg, 280 mg, 420 mg, and 560 mg tablets, as well as 140 mg capsules. Patients currently taking this medication are affected by this safety notice.
- Product
- IMBRUVICA (ibrutinib), 140 mg, 280 mg, 420 mg and 560 mg tablets, and 140 mg capsules
- Reason
- New safety information - Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-08-29
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/440ee176-de79-48f9-bf5a-1cc1956ec235